CINGW
Cingulate Inc.
—
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Price History
Fundamentals
| Market Cap | - |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-1.73 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -198.74% |
| Debt/Equity | 26.81 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | - |
| Beta | -0.89 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $0.01 |
| 52-Week Low | $0.01 |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | 2.5K |
Performance Analysis
NEUTRALCINGW presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Sep 09, 2026 02:13 UTC
Back to Screener Export Report